EGFR L718Q

CI-VAR-00002387Explore in graph →CIViC 2999

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma4
EGFR L718Q	Erlotinib + OsimertinibCombination	Predictive	D	Supports Sensitivity Response	3	submitted	EID8081 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. A set of osimertinib resistant tumours were treated with 25mg/kg osimertinib and 2… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
EGFR L718Q	Osimertinib	Predictive	D	Supports Resistance	4	submitted	EID8058 A genetically engineered mouse model of lung adenocarcinoma (LUAD) was created expressing human EGFR L858R transgene. Mice were treated with either daily 5mg/kg, followed by 25mg/kg after tumour recur… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm2
EGFR L718Q	Afatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID8071 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with afatinib suppressed EGFR phosphorylation of L858R+L797S, and caused complete inhibition… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic
EGFR L718Q	Erlotinib	Predictive	D	Supports Resistance	3	submitted	EID8075 Preclinical models of osimertinib-resistant EGFR mutants were treated with erlotinib or afatinib. Treatment with erlotinib suppressed phosphorylation of EGFR L858R+C797S and to a lesser extent EGFR L8… (full text at CIViC) PMID 32193290 · Starrett et al., 2020 · Open in CIViC	civic